Trade KZIA stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Kazia Therapeutics Limited American Depositary Shares (KZIA) is trading at US$9.35, up 0.86% today as of Oct 5, 16:00 EDT. The company has a market capitalisation of US$153.18M. Over the past 52 weeks, KZIA has traded between US$4.86 and US$17.40. On Syfe you can trade KZIA with $0 commission and add it to your watchlist.
| Previous close | US$9.27 |
|---|---|
| Market cap | US$153.18M |
| 52-week range | US$4.86 – US$17.40 |
| Volume | 240.09K |
| Exchange | US |
Kazia Therapeutics Limited American Depositary Shares
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Year: 1999
Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study
Sep 1, 12:30 PM · MT Newswires
Kazia Therapeutics Expands Paxalisib Trial Into HR+/HER2- Breast Cancer
Sep 1, 11:57 AM · MT Newswires
Kazia Therapeutics Prices $40 Million Public Offering
Aug 28, 12:00 PM · MT Newswires
Kazia Therapeutics Achieves 100% Clinical Benefit Rate in Initial Patients for Advanced Triple-Negative Breast Cancer
Aug 27, 9:44 PM · MT Newswires
Kazia Therapeutics Proposes Tranched Public Offering
Aug 27, 9:41 PM · MT Newswires
Stay on top of KZIA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
